Quick New Member Take: 3 Questions to Inossia

Medicon Village

We are delighted to introduce new Medicon Village members in an ongoing series. This time, we are featuring Inossia, a new resident of The Spark building, represented by Anette Israelsson.

Why have Inossia chosen to join Medicon Village?

This move brings us closer to many innovative companies in the life sciences sector, providing a fantastic environment for collaboration and growth. The active networking opportunities at Medicon Village, including industry-focused groups in areas like regulatory affairs, quality assurance, and medical writing are some of the activities we find very useful.

What are Inossia’s key objectives for your operations in the Nordics?

Inossia was founded in Sweden in 2013 as a spin-off company from Uppsala University. Our main solution in spinal care requires a lot of extensive testing to make sure that our solution is safe to use in patients. We continue to do most of our internal testing at state of the art lab in Uppsala University. Additionally, the company actively explores new solutions to expand its product portfolio, making its partnership with the university vital for innovation and development in the Nordics.

What are your business’s major challenges for the upcoming year to meet market demand and trends?

Approval of Class III medical devices is always a challenge. We are currently working towards applying for FDA and MDR regulatory approval for the cement V-Flex, which is the first bone cement to use our innovative Inossia® Cement Softener.

 

For more information on Inossia, visit https://www.inossia.com.